Editas Medicine Inc
(NASDAQ:EDIT)
$7.055
-0.05[-0.70%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
$7.09
0.0350[0.50%]
Open7.100Close7.055
Vol / Avg.1.694M / 1.403MMkt Cap575.918M
Day Range6.980 - 7.43052 Wk Range6.330 - 14.220

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Editas Medicine Stock (NASDAQ:EDIT), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Neutral

Highest Price Target1

$65.00

Lowest Price Target1

$7.00

Consensus Price Target1

$20.85

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
52512

Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Oppenheimer
  • Chardan Capital
  • Raymond James
  • RBC Capital

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Editas Medicine

All Ratings (64)

Upgrades (5)

Downgrades (6)

Initiations (9)

Q

What is the target price for Editas Medicine (EDIT)?

A

The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Editas Medicine (EDIT)?

A

The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.

Q

When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.

Q

Is the Analyst Rating Editas Medicine (EDIT) correct?

A

While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.